Literature DB >> 8565533

Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease.

C W Hanson1, B E Marshall, H F Frasch, C Marshall.   

Abstract

OBJECTIVES: To compare data derived from a computer model of the pulmonary circulation with data from a case series of patients with chronic obstructive pulmonary disease (COPD). To evaluate the specific factors contributing to CO2 retention due to oxygen therapy in patients with acute exacerbations of COPD.
DESIGN: Data from a computer model of the pulmonary circulation were compared with a previous case series. PATIENTS: Patient data were derived from previous case series.
INTERVENTIONS: Simulated application of oxygen therapy.
MEASUREMENTS AND MAIN RESULTS: The computer model of the pulmonary circulation generates data comparable with those data from a series of patients with COPD treated with supplemental oxygen and permits identification of the causes for hypercarbia. Therapy with supplemental oxygen alters hypoxic pulmonary vasoconstriction and modulates the Haldane effect, resulting in changes in physiologic deadspace.
CONCLUSION: Changes in physiologic deadspace are sufficient to account for the hypercarbia developed by patients with acute exacerbations of COPD when treated with supplemental oxygen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8565533     DOI: 10.1097/00003246-199601000-00007

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  12 in total

1.  Collaborative prototyping approaches for ICU decision aid design.

Authors:  L S Ehrhart; C W Hanson; B E Marshall; C Marshall; C Medsker
Journal:  Proc AMIA Symp       Date:  1999

Review 2.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

Review 3.  Submissive hypercapnia: Why COPD patients are more prone to CO2 retention than heart failure patients.

Authors:  Chi-Sang Poon; Chung Tin; Gang Song
Journal:  Respir Physiol Neurobiol       Date:  2015-04-17       Impact factor: 1.931

4.  Behavioural responses to environmental hypercapnia in two eusocial species of African mole rats.

Authors:  Travis Branigan; Sulaf Elkhalifa; Matthew E Pamenter
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2018-09-01       Impact factor: 1.836

5.  Treatment of hypoxemia during xylazine-tiletamine-zolazepam immobilization of wapiti.

Authors:  M R Read; N A Caulkett; A Symington; T K Shury
Journal:  Can Vet J       Date:  2001-11       Impact factor: 1.008

6.  Oxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients: From Pathophysiology to Clinical Practice.

Authors:  Alexander Thomas; Sean van Diepen; Rachel Beekman; Shashank S Sinha; Samuel B Brusca; Carlos L Alviar; Jacob Jentzer; Erin A Bohula; Jason N Katz; Andi Shahu; Christopher Barnett; David A Morrow; Emily J Gilmore; Michael A Solomon; P Elliott Miller
Journal:  JACC Adv       Date:  2022-08-26

Review 7.  Should We Use High-Flow Nasal Cannula in Patients Receiving Gastrointestinal Endoscopies? Critical Appraisals through Updated Meta-Analyses with Multiple Methodologies and Depiction of Certainty of Evidence.

Authors:  Chi Chan Lee; Teressa Reanne Ju; Pei Chun Lai; Hsin-Ti Lin; Yen Ta Huang
Journal:  J Clin Med       Date:  2022-07-03       Impact factor: 4.964

8.  Acute Responses to Oxygen Delivery via High Flow Nasal Cannula in Patients with Severe Chronic Obstructive Pulmonary Disease-HFNC and Severe COPD.

Authors:  Amy H Attaway; Jihane Faress; Frank Jacono; Srinivasan Dasarathy
Journal:  J Clin Med       Date:  2021-04-21       Impact factor: 4.241

Review 9.  Respiratory complications in the postanesthesia care unit: A review of pathophysiological mechanisms.

Authors:  Marcin Karcz; Peter J Papadakos
Journal:  Can J Respir Ther       Date:  2013

Review 10.  Oxygen-induced hypercapnia in COPD: myths and facts.

Authors:  Wilson F Abdo; Leo M A Heunks
Journal:  Crit Care       Date:  2012-10-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.